Small molecule antagonists of Tcf4/β‐catenin complex inhibit the growth of HCC cells in vitro and in vivo

Hepatocellular carcinoma (HCC) is the 5th most common cancer worldwide. It is intrinsically resistant toward standard chemotherapy, making it imperative to develop novel selective chemotherapeutic agents. The Wnt/β‐catenin pathway plays critical roles in development and oncogenesis, and is dysregulated in HCC. Our study aims to evaluate the activity of 3 small molecule antagonists of the Tcf4/β‐catenin complex (PKF118‐310, PKF115‐584 and CGP049090) on HCC cell lines in vitro and in vivo. All 3 chemicals displayed dose‐dependent cytotoxicity in vitro against all 3 HCC cell lines (HepG2, Hep40 and Huh7), but were at least 10 times less cytotoxic to normal hepatocytes (from 3 donors) by using ATP assay. In HepG2 and Huh7 cells, treatment with the antagonists decreased Tcf4/β‐catenin binding capability and transcriptional activity, associated with downregulation of the endogenous Tcf4/ β‐catenin target genes c‐Myc, cyclin D1 and survivin. In HepG2 and Huh7 cells, treatment with the antagonists induced apoptosis and cell cycle arrest at the G1/S phase. All antagonists suppressed in vivo tumor growth in a HepG2 xenograft model, associated with apoptosis and reduced c‐Myc, cyclin D1 and survivin expressions. Our results suggest that these 3 antagonists of the Tcf4/β‐catenin complex are potential chemotherapeutic agents which may offer a pathway specific option for the clinical management of HCC.

[1]  Randall T Moon,et al.  WNT and beta-catenin signalling: diseases and therapies. , 2004, Nature reviews. Genetics.

[2]  W. Coleman,et al.  Mechanisms of human hepatocarcinogenesis. , 2003, Current molecular medicine.

[3]  F. Apiou,et al.  Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors , 2002, Oncogene.

[4]  D. Chan,et al.  Telomerase and c-myc expression in hepatocellular carcinomas. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  K. Uematsu,et al.  An Anti-Wnt-2 Monoclonal Antibody Induces Apoptosis in Malignant Melanoma Cells and Inhibits Tumor Growth , 2004, Cancer Research.

[6]  Xin Wei Wang,et al.  Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. , 2007, Cancer research.

[7]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .

[8]  K. Endo,et al.  Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. , 2000, Human pathology.

[9]  D. Carrasco,et al.  Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma , 2007, Proceedings of the National Academy of Sciences.

[10]  Paul Polakis,et al.  Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines , 1997, Science.

[11]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[12]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[13]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[14]  K. Sung,et al.  Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon‐α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis , 2000, Cancer.

[15]  Bert Vogelstein,et al.  Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .

[16]  A. Gardini,et al.  Liver Resection for Hepatocellular Carcinoma on Cirrhosis: Univariate and Multivariate Analysis of Risk Factors for Intrahepatic Recurrence , 2003, Annals of surgery.

[17]  R. Palmiter,et al.  Oncogene-induced liver neoplasia in transgenic mice. , 1989, Oncogene.

[18]  S. Thorgeirsson,et al.  Transgenic Mouse Model for Synergistic Effects of Nuclear Oncogenes and Growth Factors in Tumorigenesis: Interaction of c-myc and Transforming Growth Factor α in Hepatic Oncogenesis , 1993 .

[19]  Yoshiaki Miyauchi,et al.  Cyclins and cyclin‐dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis , 2003, Hepatology.

[20]  Y. Jeng,et al.  Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. , 2000, The American journal of pathology.

[21]  M. Pagano,et al.  Cyclin D1 is a nuclear protein required for cell cycle progression in G1. , 1993, Genes & development.

[22]  S. Thorgeirsson,et al.  Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. , 1993, Cancer research.

[23]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[24]  F. McCormick,et al.  A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics. , 2001, Cancer research.

[25]  Jack A. Taylor,et al.  CTNNB1 mutations and β‐catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1 † , 2001, Molecular carcinogenesis.

[26]  G. Gores,et al.  Emerging drugs for hepatocellular carcinoma , 2006, Expert opinion on emerging drugs.

[27]  B. Cieply,et al.  Unique phenotype of hepatocellular cancers with exon‐3 mutations in beta‐catenin gene , 2009, Hepatology.

[28]  M. Buendia,et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Yutaka Takigawa,et al.  Wnt signaling in liver cancer. , 2008, Current drug targets.

[30]  Q. Ye,et al.  A decade’s studies on metastasis of hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[31]  M. Kuwano,et al.  Alteration of dihydropyrimidine dehydrogenase expression by IFN-α affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells , 2007, Molecular Cancer Therapeutics.

[32]  Yasuo Ohashi,et al.  Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial , 2000, The Lancet.

[33]  M. Matsuda,et al.  β-Catenin Mutations Are Frequent in Human Hepatocellular Carcinomas Associated with Hepatitis C Virus Infection , 1999 .

[34]  K. Shiraki,et al.  Survivin promotes cell proliferation in human hepatocellular carcinoma , 2000, Hepatology.

[35]  H. Lee,et al.  Wnt/Frizzled signaling in hepatocellular carcinoma. , 2006, Frontiers in bioscience : a journal and virtual library.

[36]  A. Sparks,et al.  Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. , 1998, Cancer research.

[37]  J. Prieto,et al.  New therapies for hepatocellular carcinoma , 2006, Oncogene.

[38]  Ajamete Kaykas,et al.  WNT and β-catenin signalling: diseases and therapies , 2004, Nature Reviews Genetics.

[39]  J. Shimazaki,et al.  Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  S. Fan,et al.  β‐catenin mutation and overexpression in hepatocellular carcinoma , 2001 .

[41]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[42]  S. Monga,et al.  WNT/β‐catenin signaling in liver health and disease , 2007 .